Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

December 16, 2022

https://www.globenewswire.com/news-release/2022/12/16/2575331/0/en/Prenetics-Acquires-ACT-Genomics-Creating-a-Leader-in-Comprehensive-Cancer-Genetics-and-Precision-Oncology.html

LONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ:PRE), a leader in genomic and diagnostic testing, today announced that it is acquiring a majority stake in ACT Genomics Holdings Company Limited (“ACT”), an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and in the UK.

Read more at globenewswire.com

Related news for (PRE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.